The FDA tried to ease the concerns of drugmakers Thursday when it said that companies working on a new class of cholesterol-lowering drugs known as PCSK9 inhibitors, may not have to prove they also reduce the risks or heart attacks and strokes. The industry got concerned after two medical groups this week put out new guidelines suggesting doctors drop their emphasis on specific targets for lowering "bad" LDL cholesterol levels and focus also on using drugs that cut their risks for heart attack and stroke. Story | More